124
views
0
recommends
+1 Recommend
0 collections
    5
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

      CAPRIE Steering Committee
      Lancet (London, England)
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine have been shown to be effective, but both have potentially serious adverse effects. Clopidogrel, a new thienopyridine derivative similar to ticlopidine, is an inhibitor of platelet aggregation induced by adenosine diphosphate.

          Related collections

          Author and article information

          Journal
          Lancet
          Lancet (London, England)
          Elsevier BV
          0140-6736
          0140-6736
          Nov 16 1996
          : 348
          : 9038
          Article
          S0140673696094573
          10.1016/s0140-6736(96)09457-3
          8918275
          c572a476-9b8b-40d0-90d3-e98e764e1160
          History

          Comments

          Comment on this article